Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain

Neuropharmacology

Volumn 52, Issue 2, 2007, Pages 405-414

  Easton, Neil ^a   Steward, Carolyn ^a   Marshall, Fiona ^b   Fone, Kevin ^a   Marsden, Charles ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Amphetamine; Attention deficit hyperactivity disorder; Dopamine; Noradrenaline; Release; Vesicle

Indexed keywords

AMPHETAMINE DERIVATIVE; ATOMOXETINE; DESIPRAMINE; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; MAPROTILINE; METHYLPHENIDATE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; VANOXERINE;

ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; BIOACCUMULATION; BRAIN SLICE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG POTENCY; ELECTROSTIMULATION; IN VITRO STUDY; ISOMER; MALE; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN RELEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SYNAPSE VESICLE;

ADRENERGIC AGENTS; ANIMALS; BRAIN; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; METHYLPHENIDATE; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, BIOLOGICAL; NOREPINEPHRINE; PROPYLAMINES; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC VESICLES; SYNAPTOSOMES; TRITIUM;

EID: 33846422348     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.07.035     Document Type: Article

References (52)

1. Arnsten A.F., and Li B.M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol. Psychiatry 57 (2005) 1377-1384
2. Azzaro A.J., and Rutledge C.O. Selectivity of release of norepinephrine, dopamine and 5-hydroxytryptamine by amphetamine in various regions of rat brain. Biochem. Pharmacol. 22 (1973) 2801-2813
3. Bennett G.C., and Boarder M.R. The effect of nucleotides and adenosine on stimulus-evoked glutamate release from rat brain cortical slices. Br. J. Pharmacol. 131 (2000) 617-623
4. Berridge C.W., Page M.E., Valentino R.J., and Foote S.L. Effects of locus coeruleus inactivation on electroencephalographic activity in neocortex and hippocampus. Neuroscience 55 (1993) 381-393
5. Biederman J., and Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry 46 (1999) 1234-1242
6. Bobb A.J., Castellanos F.X., Addington A.M., and Rapoport J.L. Molecular genetic studies of ADHD: 1991 to 2004. Am J Med Genet. B Neuropsychiatr. Genet. 132 (2004) 109-125
7. Brus R., Nowak P., Szkilnik R., Mikolajun U., and Kostrzewa R.M. Serotoninergics attenuate hyperlocomotor activity in rats. Potential new therapeutic strategy for hyperactivity. Neurotox. Res. 6 4 (2004) 317-325
8. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin S.M., Gehlert D.R., and Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27 (2002) 699-711
9. Callaway C.W., Kuczenski R., and Segal D.S. Reserpine enhances amphetamine stereotypies without increasing amphetamine-induced changes in striatal dialysate dopamine. Brain Res. 505 1 (1989) 83-90
10. Castellanos F.X., Giedd J.N., Marsh W.L., Hamburger S.D., Vaituzis A.C., Dickstein D.P., Sarfatti S.E., Vauss Y.C., Snell J.W., Lange N., Kaysen D., Krain A.L., Ritchie G.F., Rajapakse J.C., and Rapoport J.L. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch. Gen. Psychiatry 53 (1996) 607-616
11. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
12. Cook Jr. E.H., Stein M.A., Krasowski M.D., Cox N.J., Olkon D.M., Kieffer J.E., and Leventhal B.L. Association of attention-deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 56 (1995) 993-998
13. Coyle J.T., and Snyder S.H. Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. J. Pharmacol. Exp. Ther. 170 (1969) 221-231
14. Davids E., Zhang K., Kula N.S., Tarazi F.I., and Baldessarini R.J. Effects of norepinephrine and serotonin transporter inhibitors on hyperactivity induced by neonatal 6-hydroxydopamine lesioning in rats. J. Pharmacol. Exp. Ther. 301 3 (2002) 1097-1102
15. Drew A.E., Derbez A.E., and Werling L.L. Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex. Synapse 38 (2000) 10-16
16. Dugast C., Suaud-Chagny M.F., and Gonon F. Continuous in vivo monitoring of evoked dopamine release in the rat nucleus accumbens by amperometry. Neuroscience 62 (1994) 647-654
17. Ernst M., Zametkin A.J., Matochik J.A., Jons P.H., and Cohen R.M. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J. Neurosci. 18 (1998) 5901-5907
18. Ferris R.M., and Tang F.L. Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypipradrol on the uptake of l-[3H]norepinephrine and [3H]dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus. J. Pharmacol. Exp. Ther. 210 (1979) 422-428
19. Ferris R.M., Tang F.L., and Maxwell R.A. A comparison of the capacities of isomers of amphetamine, deoxypipradrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta. J. Pharmacol. Exp. Ther. 181 (1972) 407-416
20. Fleckenstein A.E., and Hanson G.R. Impact of psychostimulants on vesicular monoamine transporter function. Eur. J. Pharmacol. 479 (2003) 283-289
21. Fuxe K., and Ungerstedt U. Amphetamines and Related Compounds (1970), Raven Press, New York
22. Gibson A.P., Bettinger T.L., Patel N.C., and Crismon M.L. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann. Pharmacother 40 6 (2006) 1134-1142
23. Gonzalez A.M., Walther D., Pazos A., and Uhl G.R. Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res. Mol. Brain Res. 22 (1994) 219-226
24. Hansen J.P., Riddle E.L., Sandoval V., Brown J.M., Gibb J.W., Hanson G.R., and Fleckenstein A.E. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J. Pharmacol. Exp. Ther. 300 (2002) 1093-1100
25. Harris J.E., and Baldessarini R.J. Uptake of (3H)-catecholamines by homogenates of rat corpus striatum and cerebral cortex: effects of amphetamine analogues. Neuropharmacology 12 (1973) 669-679
26. Heal D., Cheetham S., Martin M., Browning J., Luscombe G., and Buckett R. Comparative pharmacology of Dothiepin, its metabolites, and other antidepressant drugs. Drug Dev. Res. (1992) 121-135
27. Heikkila R.E., Orlansky H., Mytilineou C., and Cohen G. Amphetamine: evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J. Pharmacol. Exp. Ther. 194 (1975) 47-56
28. Holmes J.C., and Rutledge C.O. Effects of the d- and l-isomers of amphetamine on uptake, release and catabolism of norepinephrine, dopamine and 5-hydroxytryptamine in several regions of rat brain. Biochem. Pharmacol. 25 (1976) 447-451
29. Iravani M.M., and Kruk Z.L. Effects of amphetamine on carrier-mediated and electrically stimulated dopamine release in slices of rat caudate putamen and nucleus accumbens. J. Neurochem. 64 3 (1995) 1161-1168
30. Jin S., and Fredholm B.B. Electrically-evoked dopamine and acetylcholine release from rat striatal slices perfused without magnesium: regulation by glutamate acting on NMDA receptors. Br. J. Pharmacol. 121 (1997) 1269-1276
31. Johnson Jr. R.G. Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol. Rev. 68 (1988) 232-307
32. Jones S.R., Gainetdinov R.R., Wightman R.M., and Caron M.G. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18 (1998) 1979-1986
33. Knepper S.M., Grunewald G.L., and Rutledge C.O. Inhibition of norepinephrine transport into synaptic vesicles by amphetamine analogs. J. Pharmacol. Exp. Ther. 247 (1988) 487-494
34. Kuczenski R., Segal D.S., Cho A.K., and Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J. Neurosci. 15 (1995) 1308-1317
35. Liang N.Y., and Rutledge C.O. Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem. Pharmacol. 31 (1982) 983-992
36. Liang N.Y., and Rutledge C.O. Evidence for carrier-mediated efflux of dopamine from corpus striatum. Biochem. Pharmacol. 31 (1982) 2479-2484
37. Madras B.K., Miller G.M., and Fischman A.J. The dopamine transporter: relevance to attention deficit hyperactivity disorder (ADHD). Behav. Brain Res. 130 (2002) 57-63
38. Riddle E.L., Topham M.K., Haycock J.W., Hanson G.R., and Fleckenstein A.E. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur. J. Pharmacol. 449 (2002) 71-74
39. Rogeness G.A., Javors M.A., and Pliszka S.R. Neurochemistry and child and adolescent psychiatry. J. Am. Acad. Child Adolesc. Psychiatry 31 (1992) 765-781
40. Sandoval V., Riddle E.L., Hanson G.R., and Fleckenstein A.E. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J. Neurosci. 22 (2002) 8705-8710
41. Schenk J.O. The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate. Prog. Drug Res. 59 (2002) 111-131
42. Schiffer W.K., Volkow N.D., Fowler J.S., Alexoff D.L., Logan J., and Dewey S.L. Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 59 4 (2006) 243-251
43. Seeman P., and Madras B.K. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol. Psychiatry 3 5 (1998) 386-396
44. Seiden L.S., Sabol K.E., and Ricaurte G.A. Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 33 (1993) 639-677
45. Sieg K.G., Gaffney G.R., Preston D.F., and Hellings J.A. SPECT brain imaging abnormalities in attention deficit hyperactivity disorder. Clin. Nucl. Med. 20 (1995) 55-60
46. Solanto M.V. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav. Brain Res. 94 (1998) 127-152
47. Sonders M.S., Zhu S.J., Zahniser N.R., Kavanaugh M.P., and Amara S.G. Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J. Neurosci. 17 (1997) 960-974
48. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., and Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15 (1995) 4102-4108
49. Sulzer D., Sonders M.S., Poulsen N.W., and Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75 (2005) 406-433
50. Swanson J.M., Sergeant J.A., Taylor E., Sonuga-Barke E.J., Jensen P.S., and Cantwell D.P. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 351 (1998) 429-433
51. Thornburg J.E., and Moore K.E. Dopamine and norepinephrine uptake by rat brain synaptosomes: relative inhibitory potencies of 1- and d-amphetamine and amantadine. Res. Commun. Chem. Pathol. Pharmacol. 5 (1973) 81-89
52. Viggiano D., Ruocco L.A., Arcieri S., and Sadile A.G. Involvement of norepinephrine in the control of activity and attentive processes in animal models of attention deficit hyperactivity disorder. Neural Plast. 11 (2004) 133-149